Tevogen Bio Holdings Inc. (TVGN)

NASDAQ: TVGN · Real-Time Price · USD
0.8905
+0.0112 (1.27%)
Sep 5, 2025, 10:04 AM - Market open
1.27%
Market Cap175.17M
Revenue (ttm)n/a
Net Income (ttm)-31.46M
Shares Out 196.71M
EPS (ttm)-0.19
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume73,343
Open0.8600
Previous Close0.8793
Day's Range0.8600 - 0.9030
52-Week Range0.2556 - 3.0900
Beta-0.76
AnalystsStrong Buy
Price Target10.00 (+1,022.97%)
Earnings DateAug 14, 2025

About TVGN

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as L... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 18
Stock Exchange NASDAQ
Ticker Symbol TVGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to one analyst, the rating for TVGN stock is "Strong Buy" and the 12-month stock price target is $10.0.

Price Target
$10.0
(1,022.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company's pipeline product, ...

18 hours ago - GlobeNewsWire

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with...

1 day ago - GlobeNewsWire

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U...

8 days ago - GlobeNewsWire

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO D...

9 days ago - GlobeNewsWire

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding com...

10 days ago - GlobeNewsWire

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE's BEST Health Care 2025: Companie...

13 days ago - GlobeNewsWire

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a...

16 days ago - GlobeNewsWire

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and fil...

16 days ago - GlobeNewsWire

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his p...

17 days ago - GlobeNewsWire

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of hi...

17 days ago - GlobeNewsWire

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and C...

21 days ago - GlobeNewsWire

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

WARREN, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding ...

22 days ago - GlobeNewsWire

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion.

24 days ago - GlobeNewsWire

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, geneti...

24 days ago - GlobeNewsWire

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, geneti...

24 days ago - GlobeNewsWire

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

25 days ago - GlobeNewsWire

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding com...

27 days ago - GlobeNewsWire

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced it has received the previously reported $1 million in funding to a...

4 weeks ago - GlobeNewsWire

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

WARREN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding com...

4 weeks ago - GlobeNewsWire

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding ...

4 weeks ago - GlobeNewsWire

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

4 weeks ago - GlobeNewsWire

Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance ...

4 weeks ago - GlobeNewsWire

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company's significant insider ownership of outstanding common s...

5 weeks ago - GlobeNewsWire

Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House's release of “Winning the Race: America's AI Action Pl...

5 weeks ago - GlobeNewsWire

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organ...

6 weeks ago - GlobeNewsWire